Abstract. The increased incidence of cancer in recent years is associated with a high rate of mortality. Numerous types of cancer have a low percentage of CD133+ cells, which have similar features to stem cells. The CD133 molecule is involved in apoptosis and cell proliferation. The aim of this study was to determine the biological effect of CD133 suppression and its role in the chemosensitization of cancer cell lines. RT-PCR and immunocytochemical analyses indicated that CD133 was expressed in the cancer cell lines B16F10, MCF7 and INER51. Downregulation of CD133 by transfection with an antisense sequence (As-CD133) resulted in a decrease in cancer cell viability of up to 52, 47 and 22% in B16F10, MCF-7 and INER51 cancer cell lines, respectively. This decreased viability appeared to be due to the induction of apoptosis. In addition, treatment with As-CD133 in combination with cisplatin had a synergic effect in all of the cancer cell lines analyzed, and in particular, significantly decreased the viability of B16F10 cancer cells compared with each treatment separately (3.1% viability for the combined treatment compared with 48% for 0.4 µg As-CD133 and 25% for 5 ng/µl cisplatin; P<0.05). The results indicate that the downregulation of CD133 by antisense is a potential therapeutic target for cancer and has a synergistic effect when administered with minimal doses of the chemotherapeutic drug cisplatin, suggesting that this combination strategy may be applied in cancer treatment.

Introduction
Cancer is a disease in which cells lose their normal control mechanisms and exhibit unorganized growth, thus it may develop in several tissues or organs, growing and invading contiguous tissues and extending to the whole body (1). Cancer is associated with a high rate of mortality due to its capacity to disseminate rapidly and the lack of effective treatments (2-5). A number of cancer types originate from cancer stem cells (2,6-10). These cancer stem cells are important in tumor proliferation and resistance to chemotherapy and radiotherapy (11-13). Each type of tumor has a unique combination of markers that define the subpopulation of stem cells with the highest tumorigenic potential (14). For example, the stem cell marker CD133 is expressed in fetal liver but not in normal adult liver, and is re-expressed in cancer livers. This upregulation of CD133 is a factor associated with poor prognosis, suggesting that CD133 plays an oncogenic role in hepatocellular carcinoma (12,15-18).

CD133 (or Prominin 1) is a membrane glycoprotein of 120 kDa in size in humans and 115 kDa in mice (19). Cancer stem cells that are positive for CD133 exhibit the activation of a number of mechanisms responsible for tumor growth and recurrence (8-10) and inhibition of apoptosis (16,18,20,21). Observation of CD133+ cancer stem cells aids the classification, diagnosis and treatment of cancer, and a high expression of CD133 protein has been associated with lymph and visceral metastasis (22), malignancy and poor prognosis (23). The aim of this study was to determine the effect of suppression of the CD133 protein in cancer cell lines and its role in chemosensitization, with a view to contributing to our understanding of CD133 in cancer stem cells as a possible therapeutic target.

Materials and methods
Cell culture. The B16F10 murine melanoma and MCF7 breast cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and the INER51 lung cancer cell line was obtained from the National Institute of Respiratory Diseases (INER) in Mexico City, Mexico.
Cell lines were cultured and maintained in Dulbecco's modified Eagle's medium (DMEMF-12, Life Technologies, Invitrogen, Burlington, ON, Canada). The medium was supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) and cells were incubated at 37°C in a 5% CO₂ atmosphere.

**Immunocytochemistry.** B16F10, MCF7 and INER51 cells were grown on glass slides in 6-well plates (1x10⁵ cells/well) with 3 ml DMEMF-12 supplemented with 10% FBS for 24 h at 37°C and 5% CO₂, and fixed with a 1:1 aceton-methanol solution for 10 min at -20°C. The cells were rehydrated in phosphate-buffered saline (PBS) and processed for antigen retrieval by a standard microwave heating technique prior to incubation with anti-CD133 antibody (Ab-CD133; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a dilution of 1:100. The reaction was developed using the Dako Liquid DAB Substrate-Chromogen system (Dako, Carpinteria, CA, USA) and the cells were counterstained with hematoxylin and eosin.

**Construction of vector expressing antisense specific for CD133 (As-CD133).** Two primers specific for CD133 were designed using the published sequence for *Mus musculus* CD133 (GenBank accession, NM_008935; NCBI Nucleotide): CD133-1, forward: 5'-GGATCCGGTCTTGAGATCCGAGGAT-3' with the restriction site for BamHI (in bold) and reverse: 5'-GAATTCACATCCCCACGATTGAGG-3' with the restriction site for EcoRI (in bold). A 200-bp product was amplified from cDNA of B16F10 cells by 30 cycles of PCR (95°C for 60 sec, 60°C for 60 sec and 72°C for 6 sec) using TaqDNA polymerase (Invitrogen, Carlsbad, CA, USA) in a PTC-200 Peltier Thermal Cycler (MJ Research, Inc., Watertown, MA, USA). The resulting product was cloned into the vector pEGFP-N3 (Gene Therapy Systems, Inc., San Diego, CA, USA).

**Transfection with As-CD133.** B16F10, MCF7 and INER51 cell lines were transfected with As-CD133 and pEGFP-N3 plasmid as a control (Clontech Laboratories, Inc., Palo Alto, CA, USA) using the cationic branched polymer polyethylenimine 25 kDa (PEI) (Sigma-Aldrich, St. Louis, MO, USA) using the cationic branched polymer polyethylenimine 25 kDa (PEI) (Sigma-Aldrich, St. Louis, MO, USA). A stock solution of PEI was prepared at a concentration of 6.45 µg/ml in H₂O. The charge ratio, expressed as PEI/nitrogen:DNA phosphate, was 5 (N:P=5). The cells were seeded at 3x10⁵ cells/well in 100 µl DMEMF-12 supplemented with 10% FBS in a 96-well plate 24 h before transfection. For each well, 0.1-0.6 µg of As-CD133 was diluted into 10 µl 150 mmol/l NaCl and 0.01-0.06 µl of the PEI solution was added to another 10 µl of 150 mmol/l NaCl. The PEI-NaCl solution was added to the DNA-NaCl solution, agitated and incubated for 30 min at room temperature. Then, 20 µl of the mixture was added to each well and incubated at 37°C in a 5% CO₂ atmosphere. Cell viability was evaluated by MTT assay after 48 h.

**Analysis of CD133 expression by RT-PCR (reverse transcription-polymerase chain reaction).** B16F10, MCF7 and INER51 cell lines were plated in a 6-well plate at 1x10⁵ cells/well in 3 ml DMEMF-12 supplemented with 10% FBS and incubated for 48 h at 37°C. Cells were harvested and total RNA was extracted using 1 ml TRizol reagent (Invitrogen) according to the manufacturer's instructions. For RT-PCR, 5 µg of total RNA was reverse transcribed using RT and oligo(dT) (Invitrogen).

The downregulation of CD133 mRNA in B16F10 cells transfected with As-CD133 was confirmed by PCR using a second pair of primers: CD133-2, forward: 5'-TCCAGCGAGATTGGCCTCTA-3' and reverse: 5'-CATGGTGCATTCTGCTTCTG-3', designed using the published sequence for *Mus musculus* CD133 described above. Amplification was performed for 35 cycles (95°C for 60 sec, 58.2°C for 60 sec and 72°C for 60 sec), generating a 200-bp fragment. As a control a 350-bp product of G3PDH was amplified using the primers: forward: 5'-ACCACAGTCCATGCGACCAC-3' and reverse: 5'-TCCACCAACCTTGTTGCTGA-3'. PCR products were analyzed by electrophoresis on a 0.8% agarose gel and visualized using UV light in a transilluminator (Chemi Doc, Image Lab Software, Bio-Rad, Hercules, CA, USA).

**Cell viability analysis by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.** The transfected cells were seeded in 96-well plates at a density of 3x10⁴ cells/well and allowed to attach for ~24 h at 37°C. For the MTT assay, 0.025 g MTT (Sigma-Aldrich) was added to 5 ml PBS at a concentration of 5 mg/ml MTT. The cells were incubated with 20 µl MTT solution at 37°C for 1 h. The medium was then removed, 100 µl dimethylsulfoxide was added to each well and the samples were incubated for 10 min. The optical density (OD) at 570 nm was determined using a microplate reader (Microplate Autoreader EL311, BioTek Instruments, Inc., Winooski, VA, USA). The data are shown as the percentage viability with the standard error.

**Determination of DNA integrity by acridine orange staining.** B16F10 cells (3x10⁴ cells/well in a 96-well plate) were transfected with 0.4 and 0.6 µg of As-CD133 and incubated at 37°C in a 5% CO₂ atmosphere. After 48 h, the cells were stained with 20 µl of a solution of ethidium bromide (1 mg/ml) and acridine orange (1 mg/ml) in PBS. The cells were incubated for 5 min in the dark at room temperature and then washed with PBS. The samples were photographed using fluorescence microscopy (TE-Eclipse 300, Nikon).

**RT-PCR of apoptotic genes.** cDNA of B16F10 cells was amplified using the MPCR kit for mouse apoptotic gene set-1 (Maxim Biotech, Inc., San Francisco, CA, USA) according to the manufacturer's instructions, using a PTC-200 Peltier Thermal Cycler. The PCR products were analyzed by electrophoresis on a 0.8% agarose gel and visualized under UV light in a ChemiDoc transilluminator.

**Synergistic effect of As-CD133 and cisplatin combination treatment on cancer cell viability.** B16F10, MCF-7 and INER51 cells were seeded in a 96-well plate at 3x10⁴ cells/well in 100 µl DMEMF-12 supplemented with 10% FBS 24 h prior to transfection. Subsequent to the previous procedure, the cells were transfected with 0.4 µg As-CD133 and the addition of cisplatin at the time of transfection (2-14 ng/µl resuspended in DMEMF-12 supplemented with 10% FBS). Cells were incu-
bated for 48 h at 37°C in a 5% CO₂ atmosphere and analyzed by MTT assay.

Results

Expression of CD133 in cancer cell lines. The RT-PCR analysis revealed that the three cancer cell lines analyzed, B16F10, MCF7 and INER51, all expressed high levels of CD133 mRNA (Fig. 1A). These results correlate with the immunocytochemistry, which showed that 70% of the cells were CD133⁺ (Fig. 1B).

Effect of CD133 downregulation by As-CD133 on cancer cell viability.

To determine the effect of CD133 protein downregulation in cancer cells, the three cell lines were transfected with As-CD133 or control pEGFP-N3. To determine the transfection efficiency, green fluorescent protein expression was visualized by UV microscopy, demonstrating that 70-80% of B16F10 cells were transfected, compared with only 20-30% of MCF7 and INER51 cells (Fig. 2A). Forty-eight hours after transfection with As-CD133, the three cell lines exhibited a decrease in cell viability and morphological changes. The MTT assay of cells treated with 0.6 µg As-CD133 indicated 48, 53 and 78% viability for the B16F10, MCF-7 and INER51 cancer cell lines, respectively (Fig. 2B), indicating a statistically significant difference between the control and treated B16F10 and MCF7 cell lines (P<0.05). These effects were dose-dependent (P=0.4). However, the decrease in the viability of INER51 cells was not statistically significant (P>0.05; Fig. 2B).

To investigate the correlation between the decrease in cell viability and CD133 expression, immunocytochemical and RT-PCR analyses of CD133 expression were conducted. Immunocytochemical staining showed a decrease in the CD133 protein in B16F10 cells transfected with As-CD133 (Fig. 2C). RT-PCR with primers CD133-1 corroborate the
expression by As-CD133 has a chemosensitizing effect in B16F10, MCF7 and INER51 cells, the cells were co-treated with a median lethal dose (LD₅₀) of As-CD133 (0.4 µg) and various concentrations of cisplatin (2-14 ng/µl). This combination produced a synergistic effect in B16F10 cells, since the cell viability decreased significantly with the combination treatment compared with individual treatments (3.1% viability for the combination compared with 48% viability for 0.4 µg As-CD133 and 25% for 5 ng/µl cisplatin; P<0.05). However, MCF7 and INER51 cells did not exhibit the same effect, and there was no statistical difference in cell viability between the individual and combined treatments in these cell lines (Fig. 4).

**Discussion**

Our results indicate the presence of a high percentage (≥70%) of CD133+ cells in the three cancer cell lines analyzed (B16F10 murine melanoma, MCF7 breast cancer and INER51 lung cancer cells) as assessed by immunocytochemistry. The results obtained in this study are not in agreement with those reported by Wright et al (12), who analyzed the breast cancer cell line RP1 by flow cytometry and observed that only a small percentage (2.0-5.9%) of the cells expressed CD133, or with the findings of Dou et al (13), who analyzed CD133 expression in the B16F10 murine melanoma cell line and reported a low expression of CD133+ (3.40%) using the Magnetic Activated Cell Sorting (MACS) technique. It is possible that we obtained a greater percentage of positive cells since we used a polyclonal antibody, compared with the monoclonal antibody used in the other studies.

The CD133 molecule is crucial in the survival of cancer cells, and our results showed that downregulation of the CD133 protein by an antisense construct resulted in a decrease in cancer cell viability. These results support the findings of other authors such as Immervoll et al (24), whose data indicated that CD133 is involved in cellular polarity and is required for cellular movement as well as the processes of chemotaxis, embryonic development, invasive growth and metastasis. In addition, Yang et al (25) reported CD133 involvement in glucose metabolism and cytoskeleton alteration. Additionally, Rappa et al (7) showed that the downregulation of CD133 resulted in retarded cell growth, reduced cell motility and a decreased ability to form spheroids under stem cell-like growth conditions.

Findings of the present study also showed that the decrease in cancer cell viability following transfection with As-CD133 was most likely the result of increased cell death through an apoptotic mechanism. This pathway was likely activated via the pro-apoptotic gene p53, which was itself most likely activated by a member of the MAP kinase family, which responds to various types of stress resulting in the upregulation of p53 expression being triggered (26). However, additional studies are required to confirm this pathway.

The synergistic effect of an antisense sequence and an anticancer drug are likely to provide a good alternative treatment against CD133+ cancer since downregulation of the CD133 protein may result in chemosensitization of cancer cell lines, as observed in the B16F10 cell line used in this study. This finding presents a potentially effective and promising approach to cancer therapy, which may decrease the required...
drug dose, thereby reducing the secondary effects in patients. In a previous study, Tirino et al (19) mentioned that CD133+ cells represent a small population of cells that possess stem features and are potentially resistant to drugs, and thus may effectively drive cancer progression. Dell’Albani (16) and Liu et al (20) reported that CD133+ cells express high levels of apoptotic suppressors (Bcl2, FLIP, BCL-XL) and several apoptotic protein inhibitors (XIAP, cIAP1, cIAP2, NAIP), which are linked to caspases 3, 7 and 9 to prevent apoptosis and modulate cellular division, as well as progression of the cell cycle and signal transduction pathways (16,20).

In the present study, the synergistic effect of antisense and cisplatin was not observed in the INER51 and MCF7 cell lines. With respect to the INER 51 cell line, it is necessary to identify a more effective transfection method than polyethyleneimine since improved transfection efficiency may lead to results similar to, or even better than, those obtained with the B16F10 cells. Additionally, various drugs should be tested to obtain improved results with the MCF7 line.

In conclusion, findings of this study have provided evidence that CD133 is important in the viability of cancer cells and suggest that CD133 downregulation by antisense, alone and in combination with cisplatin, is potentially a new and powerful therapeutic strategy for CD133+ cancers.

References
1. Greenwald P and Dunn BK: Landmarks in the history of cancer epidemiology. Cancer Res 69: 2151-2162, 2009.
2. Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature 445: 851-857, 2007.
3. Jemal A, Murray T, Ward E, et al: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
4. Organización Mundial de la Salud [OMS] (2011). Cáncer. Nota descriptiva No. 297. http://www.who.int/mediacentre/factsheets/fs297/es/index.html. Accessed April 16, 2012.
5. MacKie RM, Haaschuld A and Eggermont AMM: Epidemiology of invasive cutaneous melanoma. Ann Oncol 20 (Suppl 6): v1-7, 2009.
6. Bongiorno MR, Doukaki S, Malleo F and Acriò M: Identification of progenitor cancer stem cell in lentigo maligno melanoma. Dermatol Ther 21 (Suppl 1): S1-S5, 2008.
7. Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: 3008-3017, 2008.
8. Shmelkov SV, Jun L, St Clair R, et al: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133, Blood 103: 2055-2061, 2004.
9. Beier D, Hau P, Proescholdt M, et al: CD133+ and CD133− glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010−4015, 2007.
10. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Fernando U and Camussi G: CD133+ renal progenitor cell contribute to tumor angiogenesis. Am J Pathol 169: 2223-2236, 2006.
11. Sims AH, Howell A, Howell SJ and Clarke RB: Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 4: 516-525, 2007.
12. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV and Varticovici L: Breal breast tumor contain distinct CD44+/CD24− and CD133+ cell with cancer stem cell characteristic. Breast Cancer Res 10: R10, 2008.
13. Dou J, Pan M, Wen P, et al: Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 4: 467-472, 2007.
14. Huang EH, Heidt DG, Li CW and Simeone DM: Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 141: 415-419, 2007.
15. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F and Du K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218, 2008.
16. Dell’Albani P: Stem cell marker in gliomas. Neurochem Res 33: 2407-2415, 2008.
17. Abbott A: Cancer: the root of the problem. Nature 442: 742-743, 2006.
18. Maeda S, Shinchi H, Kurahara H, et al: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 98: 1389-1397, 2008.
19. Tirino V, Desiderio V, d’Aquino R, et al: Detection and characterizaton of CD133+ cancer stem cells in human solid tumours. PLoS One 3: e3469, 2008.
20. Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
21. Shmelkov SV, Butler JM, Hooper AT, et al: CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120, 2008.
22. Al Dhaybi R, Sartelet H, Powell J and Kokta V: Expression of CD133+ cancer stem cells in childhood malignant melanoma and its correlation with metastasis. Mod Pathol 23: 376-380, 2010.
23. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107, 2007.
24. Emmervoll H, Hoem D, Sakariassen PØ, Steffensen OJ and Molven A: Expression of the stem cell marker CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48, 2008.
25. Yang C, Yang Y, Gupta N, et al: Pentaaspan membrane glycoprotein, prominin 1, is involved in glucose metabolism and cytoskeleton alteration. Biochemistry (Mosc) 72: 854-862, 2007.
26. Guo F, Li Y, Liu Y, Wang J and Li G: ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. Oncol Rep 23: 1449-1455, 2010.